Abstract

Objective: To determine if a reprise intraarticular( IA) injection of a drum- 117m colloid radiosynoviorthesis( RSO) agent can be safely given in the same joint 12 months after an original injection for treatment of canine elbow osteoarthritis( OA), and to estimate the pain reduction effect of the reprise injection.

Methods and Materials: Nine customer possessed tykes with grade 1 or 2 elbow OA were given an IA injection of drum- 117m colloid in both elbows, one of which had been treated ≤ 12 months before with the same RSO device. Common fluid analysis at birth (BL) and 180 days following treatment, as well as urinalysis, CBC, and serum chemistry analysis of individual samples obtained at BL and 180 days, were used to determine treatment safety. At BL and 180 days, radiographs, computed tomography, and MRI reviews were obtained to see if the evolution of the complaint varied between elbows that received one injection or two.

Findings: All post-treatment CBC, clinical chemistry, and urinalysis findings fell below normal limits. An examination of the common fluid revealed a significant (P = 0.0411) decline in the likelihood of monocytes at 180 days, consistent with the drum-117m colloid mode of action of pro-inflammatory macrophage death at the injection site. The progression of OA in elbows that received one or two injections did not differ significantly.

Conclusion: The drum-117m colloid can potentially provide a long-lasting curative response in children with elbow OA when administered as a reprise injection 12 months after the initial injection.